Among them is iadademstat (ORY-1001) targeting KDM1A/LSD1 and used in AML [48, 62], Ewing sarcoma [63], and triple negative breast cancer [64], but their effectiveness can be improved if combinatorial strategies with other drugs are identified. This evidence concerns the gene KDM1A and acute myeloid leukemia.